Tyra Biosciences, Inc. (TYRA)
| Market Cap | 1.93B +260.6% |
| Revenue (ttm) | n/a |
| Net Income | -131.11M |
| EPS | -2.18 |
| Shares Out | 59.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,023 |
| Open | 33.06 |
| Previous Close | 33.02 |
| Day's Range | 32.16 - 33.45 |
| 52-Week Range | 8.75 - 40.65 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 51.15 (+57.53%) |
| Earnings Date | May 13, 2026 |
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price target is $51.15, which is an increase of 57.53% from the latest price.
News
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Ty...
Tyra Biosciences initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Tyra Biosciences (TYRA) with a Peer Perform rating an no price target Tyra has dabogratinib in development for bladder cancer and achondroplasia, notes the analyst...
Tyra Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Dabogratinib is advancing in three late-stage indications—intermediate-risk NMIBC, UTUC, and achondroplasia—with pivotal data readouts expected in the coming year. The drug’s oral formulation and strong safety profile position it as a disruptive, best-in-class option in large, underserved markets.
Tyra Biosciences reports Q1 EPS (64c), consensus (59c)
As of March 31 TYRA had cash, cash equivalents and marketable securities of $383.5M. The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute…
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 20...
Tyra Biosciences Earnings release: Q1 2026
Tyra Biosciences released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Tyra Biosciences Quarterly report: Q1 2026
Tyra Biosciences has published its Q1 2026 quarterly earnings report on May 13, 2026.
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasda...
Tyra Biosciences Proxy statement: Proxy filing
Tyra Biosciences filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tyra Biosciences Proxy statement: Proxy filing
Tyra Biosciences filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tyra Biosciences initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $54 price target The firm says the company “has the right drug” to test three clinical…
Tyra Biosciences initiated with a Buy at Guggenheim
Guggenheim analyst Brad Canino initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $54 price target
Canaccord starts Tyra Biosciences at Buy into 2026 data readouts
Canaccord initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $50 price target The company is developing isoform selective FGFR inhibitors with multiple key Phase 2 data readouts…
Tyra Biosciences initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $50 price target
Tyra Biosciences price target raised to $56 from $42 at Piper Sandler
Piper Sandler raised the firm’s price target on Tyra Biosciences (TYRA) to $56 from $42 and keeps an Overweight rating on the shares heading into the stock’s two key 2026…
Tyra Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Dabogratinib is advancing in three major indications—UTUC, NMIBC, and achondroplasia—with pivotal studies and key data readouts expected this year. The oral formulation, strong safety, and high unmet need position it for rapid adoption, especially in community practices.
Tyra Biosciences reports Q4 EPS (57c), consensus (53c)
“At TYRA, we are following the science,” said Todd Harris, Ph.D., CEO of TYRA. “The strength of the genetic and biological validation behind FGFR3 gives us conviction to concentrate our…
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expecte...
Tyra Biosciences Annual report: Q4 2025
Tyra Biosciences has published its Q4 2025 annual report on March 2, 2026.
Tyra Biosciences Earnings release: Q4 2025
Tyra Biosciences released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
Tyra Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Multiple phase II trials are advancing for dabogratinib in FGFR3-driven diseases, with a focus on intermediate risk NMIBC, UTUC, and achondroplasia. Key data readouts are expected mid- and late-year, and the pipeline remains active with ongoing FGFR3 discovery efforts.
Tyra Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Tyra Biosciences (TYRA) with an Overweight rating. A constructive stance on Tyra shares is driven by three high-conviction Phase 2 clinical readouts for dabogra...
Tyra Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Tyra Biosciences (TYRA) with an Overweight rating.
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...